Chimeric antibodies
AssigneeCiba-Geigy Corporation
InventorsNorman Hardman, Laura Lee Gill, Ronald F.J. de Winter, Kathrin Wagner, Christoph Heusser
Life of this patent
Estimating the term…
Loading patent…
AssigneeCiba-Geigy Corporation
InventorsNorman Hardman, Laura Lee Gill, Ronald F.J. de Winter, Kathrin Wagner, Christoph Heusser
Estimating the term…
The invention relates to murine/human chimeric monoclonal antibodies with high specificity to and affinity for human carcinoembryonic antigen (CEA), derivatives thereof, processes for the preparation of these antibodies and their derivatives, DNAs coding for heavy and light chains of these antibodies, processes for the preparation of said DNAs, mammalian cell lines that produce and secrete the antibodies and processes for the preparation of said cell lines. The chimeric antibodies and their derivatives are used for clinical purposes in vitro and in vivo, especially for the diagnosis of cancer, for localization and in vivo imaging of tumors, for therapy, e.g. site-directed delivery of cytotoxins, and similar purposes. The invention also concerns test kits and pharmaceutical compositions containing said chimeric monoclonal antibodies and/or derivatives thereof.
A chimeric monoclonal antibody and derivatives thereof consisting of variable regions of mouse origin and human constant regions, which recognize epitopes of CEA not present on non-specific cross-reacting antigen NCA.sub.55 and NCA.sub.95, on biliary glycoprotein, or on granulocytes.
Dependencies are inferred from the claim text.